| Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage … ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ... The Lancet 387 (10024), 1163-1177, 2016 | 2217 | 2016 |
| European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines JA Witjes, HM Bruins, R Cathomas, EM Compérat, NC Cowan, G Gakis, ... European urology 79 (1), 82-104, 2021 | 2026 | 2021 |
| Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer JA Witjes, T Lebret, EM Compérat, NC Cowan, M De Santis, HM Bruins, ... European urology 71 (3), 462-475, 2017 | 1930* | 2017 |
| Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial M Pless, R Stupp, HB Ris, RA Stahel, W Weder, S Thierstein, MA Gerard, ... The Lancet 386 (9998), 1049-1056, 2015 | 411 | 2015 |
| Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer J Beyer, P Albers, R Altena, J Aparicio, C Bokemeyer, J Busch, ... Annals of oncology 24 (4), 878-888, 2013 | 334 | 2013 |
| ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up F Honecker, J Aparicio, D Berney, J Beyer, C Bokemeyer, R Cathomas, ... Annals of oncology 29 (8), 1658-1686, 2018 | 327 | 2018 |
| Serum levels of microRNA-371a-3p (M371 test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study KP Dieckmann, A Radtke, L Geczi, C Matthies, P Anheuser, U Eckardt, ... Journal of Clinical Oncology 37 (16), 1412-1423, 2019 | 326 | 2019 |
| SAKK 16/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non–small-cell lung cancer—a multicenter single-arm phase II trial SI Rothschild, A Zippelius, EI Eboulet, S Savic Prince, D Betticher, ... Journal of clinical oncology 39 (26), 2872-2880, 2021 | 248 | 2021 |
| The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma R Cathomas, A Lorch, HM Bruins, EM Compérat, NC Cowan, ... European urology 81 (1), 95-103, 2022 | 238 | 2022 |
| Current best practice for bladder cancer: a narrative review of diagnostics and treatments E Compérat, MB Amin, R Cathomas, A Choudhury, M De Santis, A Kamat, ... The Lancet 400 (10364), 1712-1721, 2022 | 225 | 2022 |
| STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive … ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ... Lancet 387 (10024), 1163-1177, 2016 | 224 | 2016 |
| Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international … RA Stahel, O Riesterer, A Xyrafas, I Opitz, M Beyeler, A Ochsenbein, ... The Lancet Oncology 16 (16), 1651-1658, 2015 | 223 | 2015 |
| EAU-ESMO Consensus statements on the management of advanced and variant bladder cancer—an international collaborative multistakeholder effort†: under the auspices of the EAU … JA Witjes, M Babjuk, J Bellmunt, HM Bruins, TM De Reijke, M De Santis, ... European urology 77 (2), 223-250, 2020 | 203 | 2020 |
| Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients … A Papachristofilou, MM Hipp, U Klinkhardt, M Früh, M Sebastian, C Weiss, ... Journal for immunotherapy of cancer 7, 1-14, 2019 | 188 | 2019 |
| Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). ND James, MR Sydes, MD Mason, NW Clarke, DP Dearnaley, MR Spears, ... Journal of Clinical Oncology 33 (15_suppl), 5001-5001, 2015 | 186 | 2015 |
| Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study M Schuler, BC Cho, CM Sayehli, A Navarro, RA Soo, H Richly, ... The Lancet Oncology 20 (10), 1454-1466, 2019 | 170 | 2019 |
| Sensitivity comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase II imaging study GP Nicolas, N Schreiter, F Kaul, J Uiters, H Bouterfa, J Kaufmann, ... Journal of Nuclear Medicine 59 (6), 915-921, 2018 | 155 | 2018 |
| Active surveillance is the preferred approach to clinical stage I testicular cancer CR Nichols, B Roth, P Albers, LH Einhorn, R Foster, S Daneshmand, ... Journal of Clinical Oncology 31 (28), 3490-3493, 2013 | 148 | 2013 |
| Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08) AJ Templeton, V Dutoit, R Cathomas, C Rothermundt, D Bärtschi, ... European urology 64 (1), 150-158, 2013 | 148 | 2013 |
| Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV … M Sebastian, A Papachristofilou, C Weiss, M Früh, R Cathomas, W Hilbe, ... BMC cancer 14, 1-10, 2014 | 143 | 2014 |
Roger von MoosHead of medical Oncology Cantonal Hospital GraubuendenVerificeret mail på ksgr.ch
